Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 10 of 11 descriptions
| No. | 薬物名（臨床試験情報から抽出） | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | DEXMEDETOMIDINE | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬1. DEXMEDETOMIDINE
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 14件: 2 2, 4, 6, 21, 34, 46, 70, 107, 113, 171, 212, 215, 226, 280 💬1. DEXMEDETOMIDINE
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | Dexmedetomidine 1 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬2. Dexmedetomidine 1
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬2. Dexmedetomidine 1
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 3 | Dexmedetomidine 2 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬3. Dexmedetomidine 2
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬3. Dexmedetomidine 2
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 4 | Dexmedetomidine 3 | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬4. Dexmedetomidine 3
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 280 280 💬4. Dexmedetomidine 3
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 5 | Dexmedetomidine group | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬5. Dexmedetomidine group
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬5. Dexmedetomidine group
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 6 | Dexmedetomidine Hcl 100 Mcg/mL Inj | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬6. Dexmedetomidine Hcl 100 Mcg/mL Inj
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 215 215 💬6. Dexmedetomidine Hcl 100 Mcg/mL Inj
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 7 | DEXMEDETOMIDINE HYDROCHLORIDE | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬7. DEXMEDETOMIDINE HYDROCHLORIDE
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 70 70 💬7. DEXMEDETOMIDINE HYDROCHLORIDE
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 8 | Dexmedetomidine Hydrochloride Infusion | 1件: Dexmedetomidine Dexmedetomidine | 1件: Dexmedetomidine
Dexmedetomidine
💬8. Dexmedetomidine Hydrochloride Infusion
| 3件: ADRA2A ADRA2A,ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬8. Dexmedetomidine Hydrochloride Infusion
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 9 | Dexmedetomidine with ropivacaine | 2件: Dexmedetomidine Dexmedetomidine,Ropivacaine | 2件: Dexmedetomidine
Dexmedetomidine
,Ropivacaine 💬 9. Dexmedetomidine with ropivacaine
| 8件: ADRA2A ADRA2A,ADRA2B, ADRA2C, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 9. Dexmedetomidine with ropivacaine
| 5件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction, cGMP-PKG signaling pathway 💬 5件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Neuroactive ligand-receptor intera ... | 1件: 70 70 💬9. Dexmedetomidine with ropivacaine
| |||||||||||||||||||||||||||||||||||||||||||||||||
| 10 | Fentanyl (Low Dose) + Dexmedetomidine | 2件: Dexmedetomidine Dexmedetomidine,Fentanyl | 2件: Fentanyl
Fentanyl
,Dexmedetomidine 💬 10. Fentanyl (Low Dose) + Dexmedetomidine
| 4件: ADRA2A ADRA2A,ADRA2B, ADRA2C, OPRM1 💬 | 4件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 4件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PK ... | 1件: 215 215 💬10. Fentanyl (Low Dose) + Dexmedetomidine
|